Physician profile
Rajiv Kumar
NPI 1851376966
$2,262.61
in general payments reported to CMS, 2019-2025
21 companies · $199 in 2025
The $199 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $120 · 2021: $192 · 2022: $374 · 2023: $566 · 2024: $445 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $658.78 | 2019-2025 | Clareon, Wavelight Refractive Suite, Lensx |
| Rxsight INC | $469.94 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Teva Pharmaceuticals USA, INC. | $197.32 | 2019-2023 | Austedo Xr |
| Carl Zeiss Meditec, INC. | $178.44 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $159.30 | 2020-2023 | |
| Glaukos Corporation | $105.80 | 2020-2024 | Idose, Photrexa |
| Sun Pharmaceutical Industries INC. | $91.73 | 2019-2025 | |
| New World Medical,INC. | $54.78 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Abbvie INC. | $48.90 | 2024-2025 | |
| Kyowa Kirin, INC. | $37.96 | 2023-2024 | Nourianz |
| Biotissue Holdings INC. | $33.78 | 2021-2022 | |
| Allergan, INC. | $31.32 | 2019-2021 | |
| Sight Sciences, INC. | $31.30 | 2019-2020 | |
| Merz North America, INC. | $26.39 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $23.79 | 2024 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $23.06 | 2020 | |
| Oyster Point Pharma, INC. | $22.05 | 2025 | Tyrvaya, Ryzumvi |
| Insightec,INC | $20.42 | 2023 | Exablate |
| Ocular Therapeutix, INC. | $17.45 | 2021 | |
| Aerie Pharmaceuticals, INC. | $16.79 | 2019 | |
| Dompe US, INC. | $13.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.